Dexcom reports Q4 revenue of $1.26 billion, provides 2026 outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Jefferies on DexCom (DXCM): 'We think the '26 guide is conservative, leaving room for upside in stock'
January 12, 2026 10:45 AM ESTJefferies analyst Matthew Taylor reiterated a Buy rating and $112.00 price target on DexCom (NASDAQ: DXCM).
The analyst comments "DXCM reported prelim 4Q25 sales of $1.26B +13% vs cons $1.24B, better than some feared. In '26, DXCM is guiding to an initial range of... More
